# Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Source: https://onco.cc/trials/nct06014658/  
OnCo record `nct06014658` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Antibody-Drug Conjugate in advanced solid tumours, run by MBrace Therapeutics, now recruiting.

## Summary

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06014658 by MBrace Therapeutics, with 130 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-07. Interventions recorded: Antibody-Drug Conjugate.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06014658
- Phase: 1/2
- Setting: A Multicenter, Open-label, Phase 1/1b / Phase 2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors
- Sponsor: MBrace Therapeutics
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06014658: https://clinicaltrials.gov/study/NCT06014658

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [MBrace Therapeutics](https://onco.cc/companies/mbrace-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06014658.json